Conference Day Two

DAY 2

7:30 am Check-in & Coffee

8:25 am Chair’s Opening Remarks

  • Fred Aslan Chief Executive Officer, Artiva Biotherapeutics, Inc

Accelerating the Road to Commercialization Through Clarity & Synchronization of Efforts

8:30 am Panel Discussion: Evaluating Safety & CMC Expectations between Different Cell Therapy Types & Autoimmune Indications

Moderator – Fred Aslan, Chief Executive Officer, Artiva Biotherapeutics

  • Jason Damiano Chief Scientific Officer, Appia Bio
  • Metin Kurtoglu Chief Medical Officer, Chief Good Manufacturing Practices & Technology Officer, Cartesian Therapeutics
  • Yongke zhang Chief Scientific Officer, IASO BioTherapeutics

Synopsis

• Discussing the advantages and disadvantages of different cell therapy modalities when meeting CMC expectations

• Understanding safety parameters that need to be demonstrated and how those may differ in various autoimmune indications

• What are some of the standards that are set or need to be set for cell therapies to advance in the autoimmune space?

• What are some of the regulatory requirements that are unique in the autoimmune space as opposed to oncology which may be challenging?

9:00 am A Comprehensive Analysis of the Cell Therapy Landscape

Synopsis

• Reviewing the current landscape of cell therapies for autoimmune diseases

• Analysis of both the preclinical and clinical stage cell therapies in development

• A review of recent deals and emerging companies in the space

9:30 am Treatment of Refractory Systemic Lupus Erythematosus with iPSC-derived Off-the-Shelf Anti-CD19 CAR T-cell Therapy

  • Vaneet Sandhu Vice President Clinical Development, Autoimmunity, Fate Therapeutics

Synopsis

  • Brief review of CAR iT cell (FT819) product configuration and clinical oncology data
  • Review of FT819 preclinical and clinical rheumatology data
  • Brief overview of CAR iNK cell (FT522) product configuration and rheumatology data

NEW DATA

10:00 am Morning Refreshment Break & Networking

Preclinical Development

Track Chair Marko Radic, Professor, University of Tennessee

Unveiling Latest Preclinical Data on Novel Upcoming Cell Therapies for Autoimmune Disease

11:00 am Scientific Rationale for g-NK Cell Therapy in Autoimmune Disease

Synopsis

• G-NK cells are a naturally occurring subset of NK cells that are permanently epigenetically modified through priming in response to CMV

• g-NK cells have multiple MOA beyond B-cell depletion: the potential to treat much larger spectrum of autoimmune diseases including multiple sclerosis where T-cells play a larger role

• Clinical development plan includes mechanism driven biomarker program for biological POC in MS

NEW DATA

11:30 am Engineering Antigen Specific TCR Based Approaches for Precision B-cell Depletion

  • Maximilian Konig Director Cellular Therapy Program Autoimmunity, John Hopkins University School of Medicine

Synopsis

• Utilizing unique antigens for selective B-cell depletion as opposed to pan approaches.

• Preliminary research on selective T-cell depletion avoiding fratricide.

NEW DATA

Clinical Strategy

Greg Deener, Chief Executive Officer, iCell Gene Therapeutics

Clinical Showcase: Highlighting Efficacy of Cell Therapy Approaches in Autoimmune Disease

11:00 am CD19-directed CAR-T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases

  • Timothy Campbell Chimeric Antigen Receptor -T Manufacturing , Training & Compliance Manager, Bristol Myers Squibb

Synopsis

• Optimized autologous CAR-T construct

• Translational data for B-cell depletion and immune reset in autoimmune patients

11:30 am Mechanistic Insights of CABA-201 in Autoimmune Disease

  • Samik Basu Chief Scientific Officer, Cabaletta Bio

Synopsis

• Clinical safety and efficacy of CABA-201 across different autoimmune diseases

• Translational data highlighting the mechanism of action of CABA-201

NEW DATA

12:00 Lunch & Networking

1:00 pm Transforming the Treatment Landscape of Autoimmune Diseases with Glycostem’s NK Cell Therapies

Synopsis

  • uNiKTM: from umbilical cord blood hematopoietic stem cells to clinically safe and efficient off-the-shelf NK cells 
  • viveNK® CAR-NK cells employ multimodal synergistic enhancement of antigen-specific targeting against SLE B cells
  • How to assess B cells depletion in autoimmune diseases? Are they really gone?

1:30 pm Preliminary Data on Selective T-cell Depletion

Synopsis

• Developing CAR NKs for selective B and T-cell depletion.

• Demonstrating efficacy of this approach in mouse models of Lupus

2:00 pm Synthetic Tregs for Treatment of Colitis

Synopsis

• Describe the synthetic Treg (synTreg) platform (Tregs produced from CD4 T-cells)

• Present efficacy data of synTregs in xeno-GvHD, mouse colitis, and humanized colitis models

NEW DATA

1:00 pm Development of CAR-Treg Therapies to Induce Immune Tolerance – Path to the Clinic

Synopsis

• Description of Quell Therapeutic’s platform to generate CAR-Treg products with enhanced safety and efficacy

• Analysis of the current outcomes from the clinical experience with CAR-Tregs in liver transplantation

NEW DATA

1:30 pm Long Term Follow-up of BCMA CD19 cCAR Therapy in Lupus

  • Greg Deener Chief Executive Officer, iCell Gene Therapeutics

Synopsis

• A complete humoral reset delivers long-term, medication-free complete remission

• Will present 2-5 year follow up in 12 lupus patients

NEW DATA

Maximizing Therapeutics Outcomes Through Effective Patient Management

2:00 pm Panel Discussion: Optimizing Patient Treatment Procedure for Best Outcomes

Moderator: Greg Deener, Chief Executive Officer, iCell Gene Therapeutics

  • Maximilian Konig Director Cellular Therapy Program Autoimmunity, John Hopkins University School of Medicine
  • David Porter Director - Cell Therapy & Transplant, Penn Medicine/ University of Pennsylvania
  • Antoine Sreih Vice President of Clinical Development, Cullinan Therapeutics

Synopsis

• Discussing regiments for patients such as ideal dosing, timing of certain procedures, and sample collection methods

• Evaluating the need for conditioning regiments such as lymphodepletion

• How long do patients need to be hospitalized?

2:30 Afternoon Break & Refreshments

Exploring the Potential of In Vivo Approaches as a Means to Meet Autoimmune Patient Demand

3:00 pm Using LNP RNA Delivery to Develop In Vivo CARs in Autoimmune Patients

  • Isin dalkilic Senior Director & Head of Drug Discovery, Orna Therapeutics

Synopsis

• Demonstrating B-cell depletion in humanized CD34 mouse models

• POC efficacy in Lupus patient blood samples

3:30 pm Insights into In Vivo CAR -Ts for Autoimmune Disease

  • Haig Aghajanian Co-Founder, Vice President & Head of Research, Capstan Therapeutics

Synopsis

• Sharing the latest learnings on efficacy of in vivo CAR-Ts

• Discussing the advantages of tLNP based delivery for mRNA encoded CARs

4:00 pm Closing Remarks

4:10 pm Close of Conference Day Two

DAY ONE
REGISTER